GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

Michael A. Nauck,Daniel R. Quast,Jakob Wefers,Juris J. Meier

DOI: https://doi.org/10.1016/j.molmet.2020.101102

IF: 8.568

2021-04-01

Molecular Metabolism

Abstract:GLP-1 receptor agonists (GLP-1 RAs), with exenatide b.i.d. first approved for the treatment of type 2 diabetes in 2005, have been further developed to yield effective compounds/preparations, which have overcome the original problem of rapid elimination (short half-life), initially necessitating short intervals between injections (twice daily for exenatide b.i.d.). Today, GLP-1 RAs are injected twice daily (exenatide b.i.d.), once daily (lixisenatide, liraglutide) or once weekly (exenatide once weekly, dulaglutide, albiglutide, semaglutide). A daily oral preparation of semaglutide, which has shown a clinical effectiveness close to the once-weekly subcutaneous preparation, has recently been approved. All GLP-1 RAs share common mechanisms of action: augmentation of hyperglycaemia-induced insulin secretion, suppression of glucagon secretion at hyper- or euglycaemia, deceleration of gastric emptying preventing large post-meal glycaemic increments, reduction in calorie intake and body weight. Short-acting agents (exenatide b.i.d., lixisenatide) have reduced effectiveness on overnight and fasting plasma glucose, but maintain their effect on gastric emptying in long-term treatment. Long-acting GLP-1 RAs (liraglutide, exenatide once-weekly, dulaglutide, albiglutide, and semaglutide) have more profound effects on overnight and fasting plasma glucose and HbA1c, both on a background of oral glucose-lowering agents and in combination with basal insulin. Effects on gastric emptying decrease over time (tachyphylaxis). Given a similar, if not superior, effectiveness for HbA1c reduction with additional weight reduction and no intrinsic risk for hypoglycaemic episodes, GLP-1RAs are recommended as the preferred first injectable glucose-lowering therapy in type 2 diabetes, even before insulin treatment. However, GLP-1 RAs can be combined with (basal) insulin in either free or fixed-dose preparations. More recently developed agents, in particular semaglutide, are characterized by greater efficacy with respect to lowering plasma glucose as well as body weight. Since 2016, several cardiovascular (CV) outcomes studies have shown that GLP-1 RAs can effectively prevent CV events like acute myocardial infarction or stroke, and associated mortality. Therefore, guidelines particularly recommend treatment with GLP-1 RAs in patients with pre-existing atherosclerotic vascular disease (e.g., previous CV events). The evidence for similar effects in lower risk subjects is not quite as strong. Since sodium/glucose cotransporter-2 (SGLT-2) inhibitors treatment reduces CV events as well (with the effect mainly driven by a reduction of heart failure complications), the individual risk of ischaemic or heart failure complications should guide the choice of treatment. GLP-1 RAs may also help to prevent renal complications of type 2 diabetes. Other areas of active research in the field of GLP-1 RAs are the definition of subgroups within the type 2 diabetes population, who particularly benefit from treatment with GLP-1 RAs. This includes pharmacogenomic approaches and a characterization of non-responders. Novel indications for GLP-1 RAs outside type 2 diabetes, like type 1 diabetes, neuro-degenerative diseases, and psoriasis, are being explored. Thus, within 15 years of their initial introduction, GLP-1 RAs have become a well-established class of glucose-lowering agents which has the potential for further development and growing impact for the treatment of type 2 diabetes and potentially other diseases.

endocrinology & metabolism